الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 248 |  |  |
| | | from | 248 | | |
Abstract
The goal of any drug delivery system is to provide a therapeutic amount of a drug to a proper site in the body, so that the desired drug concentration can be achieved promptly and then maintained. The nano-targeted drug delivery systems are among the dosage forms which are developed to achieve the intention of better patient compliance, modified drug release, delivery of drug at the site of action, more efficient administration of drugs by various routes and hence better therapeutic effect. The objective of the present study was to prepare nano- particulate formulations using different polymer types. Firstly: to design pH-dependent site specific release of Naproxen (NPX) that is widely used as non steroidal anti- inflammatory drug using pH-sensitive polymers. Secondly: to prepare and evaluate nanoparticles containing Spironolactone (SPL) as a drug used for hypertension treatment. To fulfill these goals, this thesis comprises the following two parts: PART I: Formulation and Evaluation of Polymeric Naproxen-Loaded Nanoparticles. The aim of work in this part was to develop naproxen oral nanoparticles of pH-dependent site-specific release formulation with targeted drug delivery to minimize side effects of non steroidal anti-inflammatory drugs on stomach. This part was divided into three chapters: Chapter I: Formulation and Optimization of Naproxen-Loaded Eudragit L100 and Eudragit S100 Nanoparticles. This chapter dealt with the formulation and preparation of naproxen-loaded nanoparticles. Chapter II: Stability Study on the Optimized Naproxen-Loaded Nanoparticles in dried and suspended form In this chapter, the work was focused on stability study of naproxen in the optimized nanoparticles formulations. Chapter 3: In vivo Anti-inflammatory Activity of the Optimized Naproxen-Loaded Nanoparticles In this chapter, the objective was to study the anti-inflammatory action of naproxen-loaded Eudragit L100 for the optimized formula which was evaluated by carrageenan-induced hind paw edema method. Part II: Formulation and Evaluation of Polymeric Spironolactone- Loaded Nanoparticles. The aim of this part was to prepare a pharmaceutical preparation of spironolactone devoid the inherent defects of the drug for its use for hypertension treatment. Hence, the work in this part was divided into three chapters: Chapter I: Adopting Factorial Design for Formulation and Evaluation of Spironolactone-Loaded Eudragit RL100 Nanoparticles This chapter was concerned with the formulation of spironolactone-loaded nanoparticles of Eudragit RL100. Chapter II: In Vitro and Stability Study on the Optimized Spironolactone-Loaded Eudragit RL100 Nanoparticles In this chapter, the work was focused on in vitro and stability study of Spironolactone-Loaded Eudragit RL100 Nanoparticles; also, test of oral suspension of the optimized nanoparticles was accomplished.